{"nctId":"NCT03676192","briefTitle":"To Compare Efficacy and Safety of CT-P16 and European Union-Approved Avastin as First-Line Treatment for Metastatic or Recurrent Non-Squamous Non-Small Cell Lung Cancer","startDateStruct":{"date":"2019-02-01","type":"ACTUAL"},"conditions":["Adenocarcinoma of Lung"],"count":689,"armGroups":[{"label":"CT-P16","type":"EXPERIMENTAL","interventionNames":["Drug: CT-P16"]},{"label":"Avastin","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Avastin"]}],"interventions":[{"name":"CT-P16","otherNames":[]},{"name":"Avastin","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* diagnosed as recurrent disease or stage IV\n* has at least 1 measurable lesion by Response Evaluation Criteria in Solid Tumor (RECIST) Version 1.1\n\nExclusion Criteria:\n\n* has predominantly squamous cell histology non-small cell lung cancer\n* had surgery for metastatic non-squamous non-small cell lung cancer (nsNSCLC)","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Objective Response Rate (ORR) During the Induction Study Period From Central Review","description":"The ORR was defined as the proportion of patients with a confirmed Best Overall Response (BOR) of CR or PR (the 'responder'). All other patients except responders were considered as non-responders, including patients without post-baseline tumor assessment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42.40","spread":null},{"groupId":"OG001","value":"42.07","spread":null}]}]}]},{"type":"SECONDARY","title":"Response Duration From Central Review","description":"Response duration was defined as time between initial response (CR or PR) that is confirmed by the subsequent assessment after study treatment administration and PD/recurrence or death from any cause, whichever occurs first.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.60","spread":null},{"groupId":"OG001","value":"0.56","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.17","spread":null},{"groupId":"OG001","value":"0.25","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.09","spread":null},{"groupId":"OG001","value":"0.10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.08","spread":null},{"groupId":"OG001","value":"0.06","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Progression From Central Review","description":"Time to progression was defined as time from randomization to determined PD/recurrence.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.83","spread":null},{"groupId":"OG001","value":"0.81","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.29","spread":null},{"groupId":"OG001","value":"0.34","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.11","spread":null},{"groupId":"OG001","value":"0.11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.10","spread":null},{"groupId":"OG001","value":"0.06","spread":null}]}]}]},{"type":"SECONDARY","title":"Progression Free Survival From Central Review","description":"Progression-free survival was defined as time from randomization to determined PD/recurrence or death from any cause, whichever occurs first.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.73","spread":null},{"groupId":"OG001","value":"0.71","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.23","spread":null},{"groupId":"OG001","value":"0.28","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.08","spread":null},{"groupId":"OG001","value":"0.09","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.06","spread":null},{"groupId":"OG001","value":"0.04","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival","description":"Overall survival was defined as time from randomization to death from any cause.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.66","spread":null},{"groupId":"OG001","value":"0.62","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.35","spread":null},{"groupId":"OG001","value":"0.34","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.19","spread":null},{"groupId":"OG001","value":"0.21","spread":null}]}]}]},{"type":"SECONDARY","title":"Trough Serum Concentrations During the Induction Study Period","description":"Pharmacokinetic samples were collected on Day 1 of each cycle (prior to the beginning of the study drug administration) in the Induction Study Period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50426.3","spread":"39847.34"},{"groupId":"OG001","value":"52515.7","spread":"32356.13"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"73127.7","spread":"35883.59"},{"groupId":"OG001","value":"81533.7","spread":"52567.34"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"93100.6","spread":"50495.29"},{"groupId":"OG001","value":"95878.8","spread":"53977.69"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96445.2","spread":"45597.95"},{"groupId":"OG001","value":"101583.1","spread":"46275.62"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"108957.3","spread":"55135.16"},{"groupId":"OG001","value":"108512.5","spread":"49823.61"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"116188.2","spread":"58735.47"},{"groupId":"OG001","value":"114849.6","spread":"56309.70"}]}]}]},{"type":"SECONDARY","title":"Patients With Positive Anti-drug Antibodies (ADA) and Neutralizing Antibodies (NAb) at Anytime During the Whole Study Period","description":"Immunogenicity was assessed on Day 1 of Cycle 1 (pre-dose), every 2 cycles during the Induction Study Period, and every 3 cycles during the Maintenance Study Period and End of Treatment (EOT) visit. In the Follow-Up Period, immunogenicity was assessed once at the first visit of the Follow-Up Period (ninth week).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"81","spread":null},{"groupId":"OG001","value":"90","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":69,"n":345},"commonTop":["Alopecia","Anaemia","Nausea","Neutropenia","Asthenia"]}}}